Brokers Offer Predictions for Verona Pharma FY2026 Earnings

Verona Pharma plc (NASDAQ:VRNA) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Verona Pharma in a report released on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings per share of $12.56 for the year. Cantor Fitzgerald has a “Overweight” rating and a $100.00 price target on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share.

Verona Pharma (NASDAQ:VRNA) last issued its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million.

Other research analysts have also issued reports about the stock. TD Cowen began coverage on shares of Verona Pharma in a research note on Monday, April 28th. They issued a “buy” rating and a $100.00 price objective for the company. HC Wainwright increased their target price on Verona Pharma from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, June 2nd. Cowen initiated coverage on Verona Pharma in a research report on Monday, April 28th. They issued a “buy” rating for the company. Roth Capital set a $83.00 price objective on Verona Pharma in a research note on Friday, February 28th. Finally, Jefferies Financial Group increased their price objective on Verona Pharma from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $87.44.

Verona Pharma Stock Performance

NASDAQ VRNA opened at $92.50 on Wednesday. The firm has a market cap of $7.50 billion, a P/E ratio of -48.18 and a beta of 0.21. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The company’s 50 day moving average is $70.32 and its 200-day moving average is $59.90. Verona Pharma has a 12-month low of $14.14 and a 12-month high of $93.74.

Hedge Funds Weigh In On Verona Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VRNA. Frazier Life Sciences Management L.P. raised its position in shares of Verona Pharma by 2.2% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company’s stock valued at $219,539,000 after buying an additional 73,900 shares in the last quarter. Wellington Management Group LLP increased its stake in Verona Pharma by 61.0% in the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company’s stock valued at $140,492,000 after acquiring an additional 1,146,609 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Verona Pharma by 1.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company’s stock valued at $118,491,000 after acquiring an additional 32,748 shares during the last quarter. RTW Investments LP purchased a new stake in Verona Pharma during the fourth quarter valued at about $84,568,000. Finally, Janus Henderson Group PLC lifted its stake in Verona Pharma by 59.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company’s stock worth $77,466,000 after purchasing an additional 624,370 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Transactions at Verona Pharma

In related news, Director Vikas Sinha sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $8.92, for a total value of $178,400.00. Following the transaction, the director now directly owns 74,440 shares in the company, valued at approximately $664,004.80. This represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark W. Hahn sold 204,864 shares of the firm’s stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $9.33, for a total transaction of $1,911,381.12. Following the completion of the sale, the chief financial officer now directly owns 12,678,992 shares in the company, valued at $118,294,995.36. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,085,800 shares of company stock valued at $10,014,481. 4.80% of the stock is currently owned by company insiders.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.